Advocacy intelligence hub — real-time data for patient organizations
DUVYZAT: FDA approved
treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
DUVYZAT
(GIVINOSTAT)Orphan drugItalfarmaco SPA
Satellos Chief Medical Officer
Satellos Bioscience, Inc.
📍 Los Angeles, California
Laurent Servais, MD, PhD
University of Liege
📍 Liège
Daniel Natera-de Benito, M.D
Hospital Sant Joan de Déu
📍 GAINESVILLE, FL
Anna Codina
Applied Research in Neuromuscular Diseases
Katherine D Mathews
Carver College of Medicine
Jennifer G Andrews
College of Medicine
View all Duchenne and Becker muscular dystrophy specialists →